Pictet North America Advisors 13F: New $647K Stake in BIIB
Key Points
- Pictet North America Advisors initiated a new holding in Biogen Inc. BIIB by acquiring 2,865 shares worth about $647,146, as shown in an October 21, 2026 Form 13F filing.
- Biogen shares recently traded around $240.81, sitting 74.5% above their 52-week low and close to the company's 52-week peak.
- Primecap Management Company grew its holdings in the biotechnology firm by 2.7%, ending the period with 15,154,606 shares worth about $3.73 billion.
Get Biogen text alerts
We text you when insiders, Congress, analysts or big funds move on $BIIB.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Biogen Inc. alert may contain errors. Disclosures
Pictet North America Advisors opened a new stake in Biogen Inc. BIIB by purchasing 2,865 shares valued at about $647,146. The investment came to light in a Form 13F filing submitted to the U.S. Securities and Exchange Commission on October 21, 2026. Biogen closed at $240.98 on the day of the filing.
BIIB
Biogen Inc.
Pictet North America Advisors vs. the S&P 500
Hypothetical returns from Pictet North America Advisors's disclosed trades, not real profit or advice. How we model this.
What Changed in Pictet North America Advisors's Biogen Position
The fund established a fresh position in the Cambridge, Massachusetts-based drug maker during the quarter, bringing its total ownership to 2,865 shares.
Other Institutional Activity in Biogen
Other large funds have also adjusted their stakes in the biotechnology company recently. Primecap Management Company grew its holdings by 396,980 shares, ending with 15,154,606 shares worth about $3.73 billion.
Biogen Inc. Stock Down 0.1%
Biogen shares recently traded around $240.81, sitting about 2.3% below their 52-week high of $246.54 and 74.5% above their 52-week low of $138.00. The stock trades comfortably above its 50-day moving average of $221.68 and its 200-day moving average of $198.77. The company carries a market capitalization of roughly $36.34 billion and a trailing P/E ratio of 43.68, while its forward P/E sits at 14.96.
Recent Earnings
Biogen reported trailing twelve month revenue of $10.03 billion alongside an EPS of $5.63. The company's next quarterly financial results are scheduled for release on October 28, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
5 target raises vs 1 cuts.
-
EPS & revenue
EPS beat estimates by 26.3%. Revenue beat estimates by 7.7%.
-
Profit surprise
EBITDA missed by 7 percent. Operating income missed by 14 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
5 target raises, 1 target cut.
-
Earnings quality
Gross margin down 2.9 points. Operating margin down 14.1 points. Positive free cash flow.
Earnings Call Summary
Biogen had a very strong first quarter with growth products generating 851 million dollars, up 12 percent year-over-year. LEQEMBI sales surged 74 percent to 168 million dollars, benefiting from expansion in the U.S., Japan, and China. The company highlighted real-world evidence showing nearly 80 percent of LEQEMBI patients remain on therapy at 18 months, supporting the durability of treatment. High-dose SPINRAZA launched successfully with 20 percent of U.S. patients already switching, and the company is preparing for multiple pipeline readouts starting this year, including data on tau-targeting drug BIIB080 and lupus candidate Litifilimab.
Guidance Biogen reaffirmed its full-year guidance, confident in underlying business strength. The company expects to close the Apellis acquisition in the second quarter and will provide combined guidance after close. Management noted about 600 million dollars of contract manufacturing revenue expected this year, roughly two-thirds in the first half. They anticipate the acquisition will be accretive to earnings per share in 2027.
Slightly positive report. The quarter was acceptable, but the forward setup is not strong.
Insider Buying and Selling at Biogen Inc.
Recent insider moves show varied transactions across the executive team and board. On February 9, 2026, officer Priya Singhal sold 2,660 shares at an average price of $199.83 for a total value of $531,548. A few days later, on February 12, 2026, officer Nicole Murphy bought 3 shares at $195.04 for $585. Later, on August 4, 2026, director Lloyd B. Minor disposed of 1,186 shares valued at $239,750.
Analysts Set New Price Targets
Wall Street analysts have updated their outlooks on the stock ahead of upcoming results. On October 8, 2026, RBC Capital maintained an Outperform rating and adjusted its price target to $256.00 from $260.00. UBS maintained a Buy rating on October 9, 2026, raising its target to $270.00 from $240.00. JP Morgan upgraded the stock to Overweight on October 12, 2026, lifting its target to $300.00 from $210.00. Wells Fargo maintained an Overweight rating on October 20, 2026, boosting its target to $310.00 from $250.00. Finally, TD Cowen maintained a Buy rating on October 21, 2026, moving its target to $250.00 from $225.00. Across the broader analyst community, the stock carries a consensus Buy recommendation and a mean price target of $247.32.
About Biogen Inc.
Biogen Inc. discovers, develops, and manufactures therapies focusing on neurological and rare diseases. The company provides specialized treatments to patients in the United States and international markets.
Bottom Line
Institutional interest in Biogen remains steady as the company prepares for its next earnings report on October 28, 2026. Observers will be watching to see if quarterly financial updates align with recent analyst target increases.
Related Filing Alerts
Source: Pictet North America Advisors's 13F filing on $BIIB (Oct 21, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts